Articles by Christopher Allen - BioPharm International



Articles by Christopher Allen

Christopher Allen

Dr. Reddy's to Relocate North America HQ
April 10, 2013

Dr. Reddy's Laboratories has announced plans to relocate its North America headquarters and establish a R&D facility in Princeton, New Jersey.

INTERPHEX 2013 Announces Conference Program
March 1, 2013

INTERPHEX 2013 to be held April 23–25, 2013, at the Javits Center in New York will highlight pharmaceutical regulation QA/QC, product development, facility, process design, manufacturing, packaging, and supply chain programs.

Merck and Samsung Bioepis Form Biosimilars Development and Commercialization Agreement
February 20, 2013

Merck and Samsung Bioepis have formed an agreement to develop and commercialize multiple prespecified and undisclosed biosimilar candidates.

Mylan, Biocon Form Pact to Develop and Commercialize Insulin Products
February 15, 2013

Mylan has entered into a definitive agreement with Biocon Limited for an exclusive collaboration on the development and commercialization of generic versions of three insulin analog products.

Biogen Acquires Full Tysabri Rights from Elan
February 7, 2013

Biogen Idec has agreed to acquire full Tysabri rights from Elan, and will use its existing cash reserves to make a payment of $3.25 billion to Elan upon the closing of the transaction and make future contingent payments to Elan.

Pfizer Reports Fourth-Quarter and Full-Year 2012 Financial Results
February 1, 2013

Pfizer has reported financial results for fourth-quarter and full-year 2012. Fourth-quarter 2012 revenues were $15.1 billion, a decrease of 7% compared with $16.1 billion in the year-ago quarter, which reflects an operational decline of $802 million, or 5%, and the unfavorable impact of foreign exchange of $271 million, or 2%.

Actavis Unveils Long-Term Growth Strategy
January 25, 2013

Following its recent acquisition, Actavis (formerly Watson Pharmaceuticals) unveiled its long-term growth strategy during its investor meeting in New York.

FDA Approves New Influenza Vaccine Manufactured with Novel Technology
January 18, 2013

FDA has approved Protein Sciences's FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human flu vaccine. FDA approved FluBlok for people 18–49 years old.

Upstream, Downstream Processing in Motion
November 2, 2012

GE Healthcare Life Sciences' ReadyToProcess platform aims to streamline bioprocessing.



Click here